Literature DB >> 1319616

The mode of action of CY216 and CY222 in plasma.

S Béguin1, S Wielders, J C Lormeau, H C Hemker.   

Abstract

Three fractions of the low molecular weight heparin CY216 (fraxiparin, mean molecular weight [MMW] 5,090), with MMWs of respectively, 3,090, 4,400 and 7,910 were prepared by gel permeation chromatography. From CY222 (MMW 3,770) as well as from CY216 and its three fractions the material with high affinity to antithrombin III (AT III) was obtained by chromatography on immobilised AT III. The molecular weight distribution of each of the ten preparations thus obtained was determined by high performance liquid chromatography, while the content of AT III binding material was determined by stoichiometric titration of AT III, monitored by intrinsic fluorescence enhancement. We measured the effect of all heparins on the decay of endogenous thrombin in plasma and on the overall generation of thrombin in plasma, triggered via the extrinsic or via the intrinsic pathway. From these data we calculated the time course of prothrombin conversion, i.e. the course of factor Xa activity as expressed by prothrombinase activity. It was found that in platelet-poor plasma the anticoagulant properties of the heparins are largely dependent on their antithrombin action, which is determined by their content of high affinity material with a MW of 5,400 or higher. The specific antithrombin activity of all heparins, when expressed in terms of material with high affinity to antithrombin III (HAM) with a MW greater than 5,400 is 13.0 min-1/(microgram/ml) (range 10.5-15.9).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1319616

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

1.  Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.

Authors:  M Azizi; C Veyssier-Belot; M Alhenc-Gelas; G Chatellier; E Billaud-Mesguish; J N Fiessinger; M Aiach
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

Review 2.  Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  R Davis; D Faulds
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 3.  Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.

Authors:  L B Barradell; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

4.  Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation.

Authors:  Saartje Bloemen; H Coenraad Hemker; Raed Al Dieri
Journal:  Haematologica       Date:  2012-10-25       Impact factor: 9.941

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.